Search Within

Department of Medicine

  1. "Asia-Pacific Journal of Clinical Oncology"
Formats
  1. Meeting Abstract (55)
  2. Journal Article (3)
Groups
  1. Solid Tumor Oncology Division (57)
  2. Melanoma and Immunotherapeutics Service (22)
  3. GSK Faculty (18)
  4. Genitourinary Oncology Service (16)
  5. Thoracic Oncology (7)
  6. Melanoma Disease Management Team (6)

More Groups

People
  1. Jedd Wolchok (18)
  2. Robert Motzer (8)
  3. Michael Postow (5)
  4. Dean Bajorin (4)
  5. Paul Paik (3)
  6. Rona Yaeger (3)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2022 (7)
  4. 2021 (7)
  5. 2019 (5)
  6. 2018 (3)

More Years

Publications
  1. Asia-Pacific Journal of Clinical Oncology (58)
Publishers
  1. Wiley Blackwell (58)

Results (58)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of tumor burden at progression and changes in risk scores from baseline in patients with advanced renal cell carcinoma treated with lenvatinib + pembrolizumab: Phase 3 CLEAR trial
    Meeting Abstract

    Grünwald, V.; Keizman, D.; Bedke, J.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; more...
    Asia-Pacific Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial
    Meeting Abstract

    Gasking, S.; Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L.; Hook, E.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
    Meeting Abstract

    Haluska, P.; Pérez-Fidalgo, J. A.; Vergote, I.; Hamilton, E.; de Giorgi, U.; Van Gorp, T.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Skin adverse events of anti-cancer treatments: An examination of drug-adverse events associations
    Meeting Abstract

    Khosrotehrani, K.; Salah, S.; Pages, C.; Lacouture, M. E.; Sibaud, V.
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib by RET fusion partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 trials
    Meeting Abstract

    Solomon, B.; Drilon, A.; Park, K.; Novello, S.; Nadal, E.; Besse, B.; Peled, N.; Peterson, P.; Barker, S.; Szpurka, A. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Webber, K.; Vergote, I.; Mirza, M. R.; Coleman, R.; Fidalgo, J. A. P.; Monk, B. J.; Valabrega, G.; Slomovitz, B.; Van Gorp, T.; Moore, K.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma
    Journal Article

    Temraz, S.; Nassar, F.; Hammoud, M. S.; Mukherji, D.; O'Reilly, E. M.; Dbouk, H.; Farhat, F.; Charafeddine, M.; Faraj, W.; Khalifeh, M. J.; more...
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Zebic, D.; Stockler, M. R.; Martin, A.; Pashankar, F.; Tran, B.; Mazhar, D.; Huddart, R.; Wheater, M.; Walpole, E.; Dunwoodie, E.; more...
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)
    Meeting Abstract

    Motzer, R.; George, S.; Merchan, J. R.; Hutson, T. E.; Song, X.; Perini, R. F.; Xie, R.; Bapat, U.; Ebaid, B.; Puente, J.
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Meeting Abstract

    Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U.; Buchler, T.; Basappa, N. S.; Vidal, M. J.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save